Emerging evidence points to potential benefits of continuous glucose monitoring (CGM) well beyond use as a management tool for people with diabetes who use insulin. Until recently, CGM use had been ...

At the scientific sessions of the American Diabetes Association, multiple studies were presented showing benefits in Type 2 diabetes through a combination of continuous glucose monitoring and ...

Estimates from the International Diabetes Federation indicate that in 2021, the number of adults with diabetes in South and Central America was about 341 million. In Brazil, according to data from the ...

Patients randomized to an intensive control target of 90-130 mg/dL ended up with a similar mean glucose compared with those assigned a standard 140-180 mg/dL treatment target (170 vs 175 mg/dL, P=0.25 ...

A continuous glucose monitor is a better option than pricking your finger daily. These wearable devices are stuck to your arm and connect to an app on your smartphone or Apple Watch to easily test ...

Share on Pinterest The Signos system can be used alone, in combination with, or after GLP-1 drugs or bariatric surgery. Photography courtesy of Signos The FDA cleared the first glucose monitoring ...

Glucotrack, Inc. announced that it will present safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system at the 2025 International ...

For patients with type 2 diabetes (T2D), disparities in continuous glucose monitor (CGM) prescriptions are seen by language preference, with less access to CGM prescriptions for adult patients with ...

Add Yahoo as a preferred source to see more of our stories on Google. Your device's unique device identifier and model number are on the back of your receiver. Some of Dexcom's continuous glucose ...

Credit: Getty Images Recent evidence reveals that more patients could benefit from receiving a continuous glucose monitoring prescription as part of diabetes care from their primary provider.

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over ...